TrialSignal
Clinical trial intelligence report
A Randomized Trial Comparing Insulin Lispro Protamine Suspension With Insulin Glargine in Subjects With Type 2 Diabetes on Oral Antihyperglycemic Medications and Exenatide
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT00560417-Jul 28, 2026
NCT ID
NCT00560417
Status
COMPLETED
Phase
PHASE3
Sponsor
Eli Lilly and Company
Executive brief
Investment-Ready Snapshot
A Randomized Trial Comparing Insulin Lispro Protamine Suspension With Insulin Glargine in Subjects With Type 2 Diabetes on Oral Antihyperglycemic Medications and Exenatide is a PHASE3 clinical asset sponsored by Eli Lilly and Company in Diabetes Mellitus, Type 2. SEO and diligence focus: Insulin Lispro Protamine Suspension, Insulin Glargine, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT00560417
Indication
Diabetes Mellitus, Type 2
Modality
small molecule
Target
Insulin Lispro Protamine Suspension, Insulin Glargine
Intervention
Insulin Lispro Protamine Suspension, Insulin Glargine
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.